Cite
MLA Citation
Paul Nghiem et al.. “Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.” Journal for immunotherapy of cancer, vol. 9, no. 4, 2021, p. . http://access.bl.uk/ark:/81055/vdc_100127584137.0x000020